Abstract: Human ankyrin repeat and suppressor of cytokine signaling box protein 9 (hASB9), a subunit of an Elongin Ccullin-SOCS box (ECS) E3 ubiquitin ligase complex, is believed to be involved in specific substrate-recognition for ubiquitination and degradation. In fact, this specific substrate-recognition is determined by the ankyrin repeats of hASB9 protein. Here, we have cloned and overexpressed the hASB9-2, the splice variant of hASB9 with only one ankyrin repeat domain, as a 6His-tagged recombinant protein in Escherichia coli. The purified hASB9-2 protein was crystallized by the hanging-drop vapor-diffusion technique and diffracted to 2.2Å resolution. The data showed that the cubic hASB9-2 crystal belongs to space group P4 3 32 with unit-cell parameters (a=b=c=129.25Å, = = =90°). An asymmetric unit in the crystal was assumed to contain one protein molecule giving the Matthews Coefficient factor of 2.81 and the solvent content of 56.3%.
INTRODUCTION
The ankyrin repeat and suppressor of cytokine signaling box proteins (ASB) was first found in mice [1] . Up to now, more than 70 proteins have been found across a range of species. These proteins, which belong to a suppressor of cytokine signaling (SOCS) box protein super-family, comprise an amino terminal protein interaction motif with a variable number of ankyrin repeats and an invariable carboxyl terminal SOCS box [2] . These ASB proteins can bind to Elongin C, which associates with a complex consisting of Elongin B, Cullin-5 and a RING finger protein (Rbx1), and can finally form an Elongin C-cullin-SOCS box (ECS) protein complex [3, 4] . Acting as an E3 ubiquitin ligase, this ECS protein complex, together with an ubiquitin-activating enzyme (E1) and an ubiquitin-conjugating enzyme (E2), facilitate the polyubiquitylation and ubiquitin-proteasome mediated degradation of substrate proteins. Therefore, ASB proteins may play vital roles in regulating cellular protein levels.
In human, the ASB family has eighteen members from ASB1 to ASB18. Previous study has demonstrated that a hASB9 protein may be involved in regulating CKB abundance. The hASB9 can act as a specific substrate-recognition protein of an ECS-type E3 ubiquitin ligase complex and interact with the creatine kinase B (CKB) on a specific, ankyrin repeat dependent manner. This interaction increases polyubiquitylation of cellular CKB and decreases the total CKB levels. Furthermore, this polyubiquitylation and degradation of substrates is dependent on the SOCS box domain of hASB9 preotein [5] . The hASB9-2, the splice variant of hASB9, only contains one ankyrin repeat domain. Each ankyrin repeat composes of two anti-parallel -helices connected by a series of intervening beta-hairpin motifs, and forms a characteristic L-shaped cross-section. Consecutive repeats stack sequentially into a bundle, providing a stable platform for protein-protein interactions [6, 7] . In fact, the ankyrin repeat is loosely conserved at the amino acid level but has a highly conserved secondary structure. So far, the mechanism of how ankyrin repeats bind to specific partner molecules is still unclear. To better understand how ASB proteins bind to their specific substrates and how they determine the specificity of polyubiquitylation and degradation of substrate proteins, structure study of ASB proteins are necessary. Here we report the purification, crystallization and preliminary crystallographic studies of hASB9-2 protein, which will help us to explore the crystal structure of hASB9-2 and better understand the structural basis of interaction between hASB9-2 and CKB.
MATERIALS AND METHODS

Expression and Purification
Based on the available published sequence of a human hASB9-2 gene (GeneBank Accession No.NM_024087), the following primers were synthesized: Forward 5'-CTAGCTAGCATGGATGGCAAACAAGGGGG-3', Reverse 5'-CCGCTCGAGCCCCAAGGGATGTCAACAGA-3'. After amplification by polymerase chain reaction (PCR) from the human fetal brain cDNA library, the expected fragment of about 800 bp was cloned into the Nhe I and Xho I sites of pET-28b (Novagen, USA). The sequence of recombinant expression plasmid was confirmed by sequencing analysis of DNA both strands. E. coli Rosetta (DE3) pLyS cells transformed with the constructed expression plasmid were grown in 1 L LB medium containing kanamycin (20 mg/L) and chloramphenicol (34 mg/L). One clone was grown at 37°C until OD 600 reached 0.6-0.8 and was then induced by adding 1 mM Isopropyl-D-thiogalactopyranoside (IPTG). Induction was carried out for 12 hours at 25°C and finally cells were harvested by a centrifugation at 6000 g for 5 min.
The cell pellet was re-suspended in a standard buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 10mM imidazole pH 8.0) and ultra-sonicated on ice. The lysate was centrifuged at 14,000 g for 20 min at 4°C. The supernatant was used for purification procedure with Ni-NTA Superflow chromatography according to the manufacturer's protocol (QIAGEN). Finally, the bound 6His-tagged hASB9-2 fusion protein was completely eluted with an elution buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, and 250 mM Imidazole pH 8.0). The purity of the protein samples was analyzed by 12% SDS-PAGE gel electrophoresis and the protein concentration was determined using BCA protein assay (Pierce) with bovine serum albumin (BSA) as the standard. For crystallization, the purified hASB9-2 protein was concentrated to 21 mg/mL and phosphate buffer was replaced with 20 mM Tris-HCl buffer (pH 8.5) by ultrafiltration (Amicon-Ultra-15 concentrator 10kD. Millipore, USA).
Crystallization and X-Ray Data Collection
Preliminary crystallization conditions were screened using Crystal Screen I and II (Hampton Research, CA, USA) with the hanging-drop vapor-diffusion method at 16 o C. 1μL protein solution (21 mg/mL in Tris-HCl buffer, pH8.5) was mixed with equal volumes of reservoir solution, and equilibrated against 200μL of reservoir solution in each well. Crystals can be produced under the following conditions, 0.1 M Imidazole pH 6.5, 1.0 M Sodium acetate trihydrate, or 0.1 M HEPES pH 7.5, 2.0 M Ammonium formate, respectively. The obtained crystals appeared as cubes, which grew to their maximal size of about 0.5 0.5 0.5 mm within one week (Fig. 1) . Before data collection, a single crystal was soaked in the mother liquor containing 30% glycerol as a cryoprotectant and flash-cooled directly in the liquid nitrogen stream at -173 o C. X-ray diffraction data were exposed 3 min for each image and were collected at 100 K on a MAR Research imageplate system with a Rigaku FRE X-ray generator ( = 1.5418 Å) at the Institute of Biophysics, Chinese Academy of Sciences. One complete data set was obtained by collected 90 images with 1° oscillation. The data were processed by using HKL-2000 package [8] .
RESULTS AND DISCUSSION
The hASB9-2 protein, the splice variant of hASB9, consists of 262 amino acid residues with a calculated molecular weight of about 27.9kDa. As shown in Fig. (2) , the sequence alignment showed that both hASB9-2 and the full length human ASB9 (hASB9-1) protein share the same protein interaction motif which composed of six ankyrin repeats, while the hASB9-2 protein lacks the last 40 amino acids residues at the carboxyl terminal that consist a SOCS box domain. In this experiment, we have cloned and overexpressed the hASB9-2 as a His-tagged recombinant protein in Escherichia coli. After purification, the hASB9-2 protein was crystallized by the hanging-drop vapor-diffusion technique. Although we could obtain cubic crystals in two different conditions, condition I : 0.1 M Imidazole pH 6.5, 1.0 M Sodium acetate trihydrate and condition II : 0.1 M HEPES pH 7.5, 2.0 M Ammonium formate, the crystals qualified for Xray diffraction analysis could only be formed in condition I. The preliminary crystallographic data of hASB9-2 crystal are summarized in Table 1 . The crystal belongs to cubic space group P4 3 32 with the cell dimensions of a = b =c = 129.25 angstrom, = = =90 degrees. The asymmetric unit in the crystal was assumed to contain one protein molecule giving the Matthews Coefficient factor of 2.81 and the solvent content of 56.3%. We are trying to solve the hASB9-2 structure by molecular replacement method. The crystal structure of hASB9-2 may provide information on how hASB9-2 binds to its specific substrate CKB. The CKB, which is positively regulated by the oncogene E1a and negatively regulated by the tumor suppressor gene-p53, is overexpressed in a wide range of solid tumors and tumor cell lines [9, 10] . Therefore, determination of hASB9-2 structure would give an illustration in designing medicine that is directly targeted to the binding site of hASB9 protein in ECS complex, which may be responsible for reducing the CKB level in cancer patients and inhibit the formation and metastasis of tumors.
